~~<i id='31A7B97D29'><strike id='31A7B97D29'><tt id='31A7B97D29'><pre id='31A7B97D29'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：comprehensive 2025-09-30 06:32:05 Page View：7596

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court rules employers must be more accommodating of religious observance
Next article： Medicare details structure of new drug price negotiation program

focus

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

The simple reason for the increase in autism diagnosis

AutisticchildrenattendacourseinAulnay-sous-Bois,France.CHRISTOPHEARCHAMBAULT/AFPviaGettyImagesOnThur

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

The strange history of BMI, the body mass index

HyacinthEmpinado/STATThebodymassindex,orBMI,istheformulathat’susedmostoftentodiagnoseoverweightandob